Adaptimmune Therapeutics (ADAP)

Adaptimmune Therapeutics (ADAP) Income Statement


Adaptimmune Therapeutics Income Statement

Last quarter (Q1 2024), Adaptimmune Therapeutics's total revenue was $5.68M, a decrease of -88.07% from the same quarter last year. In Q1, Adaptimmune Therapeutics's net income was $-48.50M. See Adaptimmune Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 18.36M$ 60.28M$ 27.15M$ 6.15M$ 3.96M$ 1.12M
Cost of Revenue
Gross Profit
$ 18.36M$ 60.28M$ 27.15M$ 6.15M--
Operating Expense
$ 209.02M$ 200.02M$ 191.11M$ 168.40M$ 137.36M$ 140.89M
Operating Income
$ -190.66M$ -139.74M$ -163.97M$ -162.25M$ -133.41M$ -139.77M
Net Non Operating Interest Income Expense
----$ 2.31M$ 2.77M
Other Income Expense
$ -21.85M$ -21.24M$ 536.00K$ -3.85M$ 1.16M$ 75.00K
Pretax Income
$ -162.17M$ -112.53M$ -162.96M$ -157.30M$ -129.93M$ -136.92M
Tax Provision
$ 1.24M$ 1.34M$ 2.50M$ 791.00K$ 162.00K$ 242.00K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -163.30M$ -113.87M$ -165.46M$ -158.09M$ -130.09M$ -137.16M
Basic EPS
$ -0.12$ -0.09$ -0.17$ -0.17$ -0.90$ -1.32
Diluted EPS
$ -0.12$ -0.09$ -0.17$ -0.17$ -0.90$ -1.32
Basic Average Shares
$ 5.29B$ 1.21B$ 967.24M$ 934.83M$ 142.46M$ 104.97M
Diluted Average Shares
$ 5.28B$ 1.21B$ 967.24M$ 934.83M$ 142.46M$ 104.97M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 209.02M$ 200.02M$ 191.11M$ 168.40M$ 137.36M$ 140.89M
Net Income From Continuing And Discontinued Operation
$ -163.41M$ -113.87M$ -165.46M$ -158.09M$ -130.09M$ -137.16M
Normalized Income
$ -170.62M$ -109.33M--$ -130.09M$ -137.16M
Interest Expense
$ -162.17M$ -138.04M$ -162.96M$ -157.30M$ -133.41M$ -139.77M
$ -153.47M$ -128.20M$ -154.36M$ -145.46M$ -125.81M$ -131.76M
Currency in USD

Adaptimmune Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis